glp-1 agonists: What do GLP 1 receptor agonists actually do The anti-inflammatory and immunological properties
Description
Full escalation schedules, unit conversions, weight loss data, and switching protocols.

Semaglutide was approved in 2017 as Ozempic for diabetes, and in 2021 as Wegovy for obesity

GRADE: LOW certainty)

In late April 2025, the FDA issued a key update regarding the use of compounded GLP-1 receptor agonists like semaglutide and tirzepatide

Alpha-Lipoic Acid (ALA) adds antioxidant and metabolic support, assisting the bodys ability to utilize glucose more efficiently and support cellular energy production.*

Greger cuts through the promotional puffery and presents the pros and cons of these weight-loss drugs so individuals can make up their own mind in the face of the very real and devastating consequences of obesity
